Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| METLIFE INCMET · Entity 488 | Director | October 01, 2026 | October 05, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2026 | May 05, 2026 |
| agilon health, inc.AGL · Entity 4698 | Director | June 02, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
METLIFE INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,929 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 544 · Balance 25,929 F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,378 |
Ending reported balance
After 2026-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-01 · Grant · Acquired 943 · Balance 3,174 F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Row 2 · 2026-05-01 · Disposition to issuer · Disposed 796 · Balance 2,378 F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,787.483 |
Reported balance
After 2026-05-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-01 · Grant · Acquired 796 · Balance 7,787.483 F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 207 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 207 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.
agilon health, inc.
Report date June 02, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,633 |
Reported balance
After 2026-06-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 2,133 · Balance 7,633 F1: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director. F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026. F3: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director.
F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026.
F3: Includes restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Change Healthcare Inc.
Report date October 03, 2022 · Filed October 05, 2022
Section 16 reporting ended · disclosed 2022-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 40,706 · Balance 0 F1: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax. F2: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax.
F2: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:04 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 544 | $94.35 | $51,326.40 |
DisclosureSEC source: 0001754648-26-000015 · wk-form4_1791230692.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,929 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:02 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 157 | $95.50 | $14,993.50 |
DisclosureSEC source: 0001754648-26-000013 · wk-form4_1789070521.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,385 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:12 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 587 | $87.40 | $51,303.80 |
DisclosureSEC source: 0001754648-26-000011 · wk-form4_1781813553.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,229 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:02 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 169 | $85.57 | $14,461.33 |
DisclosureSEC source: 0001754648-26-000009 · wk-form4_1781208168.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,642 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| June 02, 2026 Filed Jun 5, 2026 01:56 UTC | agilon health, inc. AGL · Entity 4698 | GrantCommon Stock | 2,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041022 · wk-form4_1780624572.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,633 F1 · shares: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director. F2 · balance_after: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026. F3 · balance_after: Includes restricted stock units. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000875320-26-000185 · wk-form4_1778015893.xml · derivative · entry 4 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,787.483 Underlying: Common Stock · 796 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000875320-26-000185 · wk-form4_1778015893.xml · nonDerivative · entry 2 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,378 F2 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 943 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000185 · wk-form4_1778015893.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,174 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:04 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 721 | $71.17 | $51,313.57 |
DisclosureSEC source: 0001754648-26-000007 · wk-form4_1775246668.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,472 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:08 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 189 | $70.60 | $13,343.40 |
DisclosureSEC source: 0001754648-26-000005 · wk-form4_1773346077.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,751 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 639 | $80.32 | $51,324.48 |
DisclosureSEC source: 0001754648-26-000003 · wk-form4_1767733807.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,562 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:02 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 166 | $77.82 | $12,918.12 |
DisclosureSEC source: 0001754648-25-000006 · wk-form4_1765486946.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,923 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:02 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 534 | $81.93 | $43,750.62 |
DisclosureSEC source: 0001754648-25-000004 · wk-form4_1759521776.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,757 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:02 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 158 | $79.29 | $12,527.82 |
DisclosureSEC source: 0001099219-25-000216 · wk-form4_1757620953.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,223 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:32 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 562 | $77.85 | $43,751.70 |
DisclosureSEC source: 0001099219-25-000179 · wk-form4_1750451534.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,065 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:21 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 153 | $79.43 | $12,152.79 |
DisclosureSEC source: 0001099219-25-000158 · wk-form4_1749759664.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,503 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| May 28, 2025 Filed May 30, 2025 23:39 UTC | agilon health, inc. AGL · Entity 4698 | GrantCommon Stock | 78,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028721 · wk-form4_1748648358.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,543 F1 · shares: Restricted stock units that vest in full on May 28, 2026, subject to continued service as a director. F2 · balance_after: Includes restricted stock units. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 1,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000875320-25-000182 · wk-form4_1746478338.xml · derivative · entry 4 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,991.483 Underlying: Common Stock · 1,001 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2024, Ms. McKenzie deferred the receipt of 1,001 shares of common stock and received instead 1,001 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,001 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 1,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000875320-25-000182 · wk-form4_1746478338.xml · nonDerivative · entry 2 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,231 F2 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2024, Ms. McKenzie deferred the receipt of 1,001 shares of common stock and received instead 1,001 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,001 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 796 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000182 · wk-form4_1746478338.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,232 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:27 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 540 | $81.16 | $43,826.40 |
DisclosureSEC source: 0001099219-25-000111 · wk-form4_1743712031.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,350 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 20:19 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 144 | $78.45 | $11,296.80 |
DisclosureSEC source: 0001099219-25-000094 · wk-form4_1741897149.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,810 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:40 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 535 | $81.78 | $43,752.30 |
DisclosureSEC source: 0001099219-25-000026 · wk-form4_1736199599.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,667 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:33 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 132 | $82.74 | $10,921.68 |
DisclosureSEC source: 0001099219-24-000284 · wk-form4_1734557595.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,132 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 22:25 UTC | agilon health, inc. AGL · Entity 4698 | PurchaseCommon Stock | 7,500 | $2.20 | $16,488.75 |
DisclosureSEC source: 0001628280-24-050832 · wk-form4_1733955904.xml · nonDerivative · entry 2 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,819 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $2.1942 to $2.2050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · balance_after: Includes restricted stock units. Read SEC document |
| November 25, 2024 Filed Dec 11, 2024 22:25 UTC | agilon health, inc. AGL · Entity 4698 | PurchaseCommon Stock | 12,500 | $2.28 | $28,473.75 |
DisclosureSEC source: 0001628280-24-050832 · wk-form4_1733955904.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,319 F1 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 535 | $81.78 | $43,752.30 |
DisclosureSEC source: 0001099219-24-000243 · wk-form4_1727986546.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 20:32 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 141 | $74.63 | $10,522.83 |
DisclosureSEC source: 0001099219-24-000223 · wk-form4_1726173134.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,465 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:38 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 627 | $69.86 | $43,802.22 |
DisclosureSEC source: 0001099219-24-000185 · wk-form4_1718915883.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,324 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:20 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 146 | $69.06 | $10,082.76 |
DisclosureSEC source: 0001099219-24-000161 · wk-form4_1718310046.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,697 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| May 29, 2024 Filed Jun 1, 2024 00:56 UTC | agilon health, inc. AGL · Entity 4698 | GrantCommon Stock | 32,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-026128 · wk-form4_1717203400.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,819 F1 · shares: Restricted stock units that vest in full on May 29, 2025, subject to continued service as a director. F2 · balance_after: Includes restricted stock units. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 1,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000875320-24-000127 · wk-form4_1714767498.xml · derivative · entry 4 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,990.483 Underlying: Common Stock · 1,168 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2023, Ms. McKenzie deferred the receipt of 1,168 shares of common stock and received instead 1,168 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,168 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 1,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000875320-24-000127 · wk-form4_1714767498.xml · nonDerivative · entry 2 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,436 F2 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2023, Ms. McKenzie deferred the receipt of 1,168 shares of common stock and received instead 1,168 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,168 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,001 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000127 · wk-form4_1714767498.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,604 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:20 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 594 | $73.69 | $43,771.86 |
DisclosureSEC source: 0001099219-24-000118 · wk-form4_1712175628.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,550 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:48 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 129 | $71.90 | $9,275.10 |
DisclosureSEC source: 0001099219-24-000090 · wk-form4_1710794889.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,956 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 76.503 | $432.99 | $33,125.03 |
DisclosureSEC source: 0000875320-24-000006 · wk-form4_1705525544.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,822.483 Underlying: Common Stock · 76.503 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:40 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 650 | $67.35 | $43,777.50 |
DisclosureSEC source: 0001099219-24-000024 · wk-form4_1704404290.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,828 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:19 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 132 | $66.90 | $8,830.80 |
DisclosureSEC source: 0001099219-23-000291 · wk-form4_1702937959.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,178 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 89.532 | $369.98 | $33,125.05 |
DisclosureSEC source: 0001209191-23-052959 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,745.98 Underlying: Common Stock · 89.532 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:36 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 710 | $61.69 | $43,799.90 |
DisclosureSEC source: 0001099219-23-000260 · wk-form4_1696451772.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,045 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:29 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 128 | $65.93 | $8,439.04 |
DisclosureSEC source: 0001099219-23-000233 · wf-form4_169506894098524.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,335 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 89.927 | $350.79 | $31,545.49 |
DisclosureSEC source: 0001209191-23-042563 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,656.448 Underlying: Common Stock · 89.927 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:17 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 803 | $54.52 | $43,779.56 |
DisclosureSEC source: 0001099219-23-000192 · wf-form4_168746504163208.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,207 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:16 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 147 | $53.94 | $7,929.18 |
DisclosureSEC source: 0001099219-23-000169 · wf-form4_168694657956037.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,404 F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 1,449 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-027051 · doc4.xml · derivative · entry 4 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,566.521 Underlying: Common Stock · 1,449 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2022, Ms. McKenzie deferred the receipt of 1,449 shares of common stock and received instead 1,449 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,449 shares of common stock in exchange for an equal number of deferred stock units. F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027051 · doc4.xml · nonDerivative · entry 2 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,603 F2 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 1,449 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-027051 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,435 F1 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2022, Ms. McKenzie deferred the receipt of 1,449 shares of common stock and received instead 1,449 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,449 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 20:48 UTC | agilon health, inc. AGL · Entity 4698 | GrantCommon Stock | 5,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024672 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 F1 · shares: Restricted stock units that vest in full on April 14, 2024, subject to continued service as a director. F2 · balance_after: Includes restricted stock units. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 90.153 | $332.77 | $30,000.21 |
DisclosureSEC source: 0001209191-23-024705 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,117.521 Underlying: Common Stock · 90.153 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.